Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
Binding of the T-cell antigen CD4 to human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 has been reported to induce conformational rearrangements in the envelope complex that facilitate recognition of the CCR5 coreceptor and consequent viral entry into cells. To better understand the mechanism of virus docking and cell fusion, we developed a three-component gp120-CD4-17b optical biosensor assay to visualize the CD4-induced conformational change of gp120 as seen through envelope binding to a neutralizing human antibody, 17b, which binds to epitopes overlapping the CCR5 binding site. The 17b Fab fragment was immobilized on a dextran sensor surface, and kinetics of gp120 binding were evaluated by both global and linear transformation analyses. Adding soluble CD4 (sCD4) increased the association rate of full-length JR-FL gp120 by 25-fold. This change is consistent with greater exposure of the 17b binding epitope on gp120 when CD4 is bound and correlates with CD4-induced conformational changes in gp120 leading to higher affinity binding to coreceptor. A smaller enhancement of 17b binding by sCD4 was observed with a mutant of gp120, DeltaJR-FL protein, which lacks V1 and V2 variable loops and N- and C-termini. Biosensor results for JR-FL and DeltaJR-FL argue that CD4-induced conformational changes in the equilibrium state of gp120 lead both to movement of V1/V2 loops and to conformational rearrangement in the gp120 core structure and that both of these lead to greater exposure of the coreceptor-binding epitope in gp120. A 17b binding enhancement effect on JR-FL also was observed with a 32-amino acid charybdotoxin miniprotein construct that contains an epitope predicted to mimic the Phe 43/Arg 59 region of CD4 and that competes with CD4 for gp120 binding. Results with this construct argue that CD4-mimicking molecules with surrogate structural elements for the Phe 43/Arg 59 components of CD4 are sufficient to elicit a similar gp120 conformational isomerization as expressed by CD4 itself.
Zhang
W
W
Department of Medicine, School of Medicine, University of Pennsylvania, Philadelphia 19104, USA.
Canziani
G
G
Plugariu
C
C
Wyatt
R
R
Sodroski
J
J
Sweet
R
R
Kwong
P
P
Hendrickson
W
W
Chaiken
I
I
D000595:Amino Acid Sequence; D001666:Binding Sites, Antibody / Q000235:genetics; D001667:Binding, Competitive / Q000235:genetics; D015374:Biosensing Techniques; D015704:CD4 Antigens / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D018999:Charybdotoxin / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000378:metabolism*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D015497:HIV-1; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism; D018716:Molecular Mimicry; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D011485:Protein Binding / Q000235:genetics; D011487:Protein Conformation; D019713:Receptors, CCR5 / Q000378:metabolism*; D017384:Sequence Deletion; D012995:Solubility
D015704:CD4 Antigens; D018984:Epitopes, T-Lymphocyte; D015699:HIV Envelope Protein gp120; D007140:Immunoglobulin Fab Fragments; D010446:Peptide Fragments; D019713:Receptors, CCR5; D018999:Charybdotoxin